实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
9期
1276-1280
,共5页
朱明珍%徐海燕%朱志霞%蒋华
硃明珍%徐海燕%硃誌霞%蔣華
주명진%서해연%주지하%장화
非小细胞肺癌%基因多态性%HIF-1α%ERCC1
非小細胞肺癌%基因多態性%HIF-1α%ERCC1
비소세포폐암%기인다태성%HIF-1α%ERCC1
Non-smalI cell lung cancer( NSCLC)%Gene polymorphisms%HIF-1α%ERCCl
目的:探讨缺氧诱导因子-1α(HIF-1α) C1772T(C→T,rs11549465)和切除修复交叉互补基因1(ERCC1) codon 118(C→T,rs11615)基因多态性与接受顺铂方案化疗的晚期非小细胞肺癌患者疗效的关系。方法对经病理确诊的晚期NSCLC患者68例,采用含铂方案化疗2个周期后评价疗效,采用聚合酶链-限制性片段长度多态性( PCR-restric-tion fragment length polymorphism,PCR-RFLP)方法检测患者外周血HIF-1αC1772T和ERCC1 codon 118进行多态性分析,比较各基因型与晚期非小细胞肺癌患者近期疗效的相关性。结果 HIF-1αC1772T 基因型频率分别为:C/C 型占83.82%(57/68)、C/T型占16.17%(11/68),未发现T/T型;ERCC1 codon 118基因型频率分别为:C/C型占61.76%(42/68)、C/T型占32.35%(22/68)、T/T型占5.88%(4/68)。68例患者中,完全缓解(CR)1例,部分缓解(PR)21例,疾病稳定(SD)30例,疾病进展(PD)16例;总有效率为32.35%。 C/C型HIF-1αC1772T基因型患者采用铂类药物治疗的近期疗效与C/T+T/T基因型比较,差异无统计学意义( P=0.694);C/C型ERCC1基因型患者采用铂类药物治疗疗效是C/T+T/T型患者的4.125倍,差异有统计学意义(95%可信区间:1.208~14.097,P=0.019),同时携带HIF-1αC1772T C/C和ERCC1 codon 118 C/C基因型患者,对铂类药物的疗效存在一定的联合作用(P=0.001)。结论 HIF-1αC1772T和ERCC1 codon 118基因型可能是晚期NSCLC患者铂类药物敏感性的预测因子。
目的:探討缺氧誘導因子-1α(HIF-1α) C1772T(C→T,rs11549465)和切除脩複交扠互補基因1(ERCC1) codon 118(C→T,rs11615)基因多態性與接受順鉑方案化療的晚期非小細胞肺癌患者療效的關繫。方法對經病理確診的晚期NSCLC患者68例,採用含鉑方案化療2箇週期後評價療效,採用聚閤酶鏈-限製性片段長度多態性( PCR-restric-tion fragment length polymorphism,PCR-RFLP)方法檢測患者外週血HIF-1αC1772T和ERCC1 codon 118進行多態性分析,比較各基因型與晚期非小細胞肺癌患者近期療效的相關性。結果 HIF-1αC1772T 基因型頻率分彆為:C/C 型佔83.82%(57/68)、C/T型佔16.17%(11/68),未髮現T/T型;ERCC1 codon 118基因型頻率分彆為:C/C型佔61.76%(42/68)、C/T型佔32.35%(22/68)、T/T型佔5.88%(4/68)。68例患者中,完全緩解(CR)1例,部分緩解(PR)21例,疾病穩定(SD)30例,疾病進展(PD)16例;總有效率為32.35%。 C/C型HIF-1αC1772T基因型患者採用鉑類藥物治療的近期療效與C/T+T/T基因型比較,差異無統計學意義( P=0.694);C/C型ERCC1基因型患者採用鉑類藥物治療療效是C/T+T/T型患者的4.125倍,差異有統計學意義(95%可信區間:1.208~14.097,P=0.019),同時攜帶HIF-1αC1772T C/C和ERCC1 codon 118 C/C基因型患者,對鉑類藥物的療效存在一定的聯閤作用(P=0.001)。結論 HIF-1αC1772T和ERCC1 codon 118基因型可能是晚期NSCLC患者鉑類藥物敏感性的預測因子。
목적:탐토결양유도인자-1α(HIF-1α) C1772T(C→T,rs11549465)화절제수복교차호보기인1(ERCC1) codon 118(C→T,rs11615)기인다태성여접수순박방안화료적만기비소세포폐암환자료효적관계。방법대경병리학진적만기NSCLC환자68례,채용함박방안화료2개주기후평개료효,채용취합매련-한제성편단장도다태성( PCR-restric-tion fragment length polymorphism,PCR-RFLP)방법검측환자외주혈HIF-1αC1772T화ERCC1 codon 118진행다태성분석,비교각기인형여만기비소세포폐암환자근기료효적상관성。결과 HIF-1αC1772T 기인형빈솔분별위:C/C 형점83.82%(57/68)、C/T형점16.17%(11/68),미발현T/T형;ERCC1 codon 118기인형빈솔분별위:C/C형점61.76%(42/68)、C/T형점32.35%(22/68)、T/T형점5.88%(4/68)。68례환자중,완전완해(CR)1례,부분완해(PR)21례,질병은정(SD)30례,질병진전(PD)16례;총유효솔위32.35%。 C/C형HIF-1αC1772T기인형환자채용박류약물치료적근기료효여C/T+T/T기인형비교,차이무통계학의의( P=0.694);C/C형ERCC1기인형환자채용박류약물치료료효시C/T+T/T형환자적4.125배,차이유통계학의의(95%가신구간:1.208~14.097,P=0.019),동시휴대HIF-1αC1772T C/C화ERCC1 codon 118 C/C기인형환자,대박류약물적료효존재일정적연합작용(P=0.001)。결론 HIF-1αC1772T화ERCC1 codon 118기인형가능시만기NSCLC환자박류약물민감성적예측인자。
Objective To investigate the association of genetic polymorphisms of HIF-1αC1772T( C→T,rs11549465) and ERCC1codon 118(C→T,rsl1615)with the short-term efficacy of platinum drugs for advanced non-small cell lung cancer (NSCLC).Methods The genotype s of HIF-1αC1772T and ERCC1 codon 118 were determined by PCR-RFLP in 68 patients with advanced NSCLC receiving platinum-based chemotherapy.The association of different genotypes with the short-term efficacy of platinum drugs was analyzed.Results The allele frequencies of C/C,C/T and T/T of HIF-1αC1772T were 83.82%(42/68),16.17%(11/68)and 0%(0/68),respectively,1 case achieved complete response,21 cases achieved partial response,30 cases achieved stable response and 16 cases achieved progressive disease,the overall response rate was 32.35%.The response rate of HIF-1αC1772T C/C allele carriers was higher than that of C/T+T/T allele carriers,but there was no statistical signifi-cance( P=0.694);The response rate of ERCC1 codon 118 C/C allele carriers was 4.125-fold higher than that of C/T+T/T al-lele carriers,and there was significant difference (95%confidence interval:1.208~14.097,P=0.019). The two genetic poly-morphisms HIF-1αC1772T C/C and ERCC1 codon 118 C/C had some synergistic effects on the efficacy of platinum drugs( P=0.001).Conclusion The genotypes of HIF-1αand ERCC1 codon 118 maybe predictive factors for response to platinum drugs in the treatment of advanced NSCLC.